COMPASS Pathways

COMPASS Pathways develops psilocybin-based therapies for treatment-resistant depression with a focus on large Phase 3 trials and therapist-supported sessions. Its longer-duration psychedelic experience contrasts with Gilgamesh's short-acting 5-HT2AR agonist designed for a 2-hour window and potential scalability advantages post-AbbVie acquisition.